ArticleBone marrow transplantation2024

Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC.

Thomas Longval et al.PubMed ↗Publisher ↗

No numbers read from the abstract.